Tamer Yazar1, Hülya Olgun Yazar2, Emel Zayimoğlu3, Soner Çankaya4. 1. Department of Neurology, Ordu State Hospital, Ordu, Turkey. tamer.yazar@yahoo.com.tr. 2. Department of Neurology, Ordu University Education and Research Hospital, Ordu, Turkey. 3. Department of Physiotherapy, Ordu State Hospital, Ordu, Turkey. 4. Department of Biostatistics and Medical Informatics, Ordu University Medical Faculty, Ordu, Turkey.
Abstract
AIM: In this study, the aim was to identify the incidence of sarcopenia and dynapenia according to disease stage among idiopathic Parkinson's disease (IPD) patients and collect data to illuminate precautions related to reducing the disease load. METHOD: The study was completed with 166 patients divided by stage according to modified Hoehn and Yahr (HYR) criteria and 249 healthy volunteers aged from 18 to 39 and 68 to 75 years met the inclusion criteria. In our prospective and cross-sectional study, patients with IPD according to "UK Brain Bank" diagnostic criteria had the Unified Parkinson's Disease Rating Scale (UPDRS) and HYR scales applied. The patient and control groups had skeletal muscle mass index (SMMI), muscle power, and physical performance assessed. Diagnosis of sarcopenia used the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. RESULTS: In our study, in parallel with the increase in disease stage among IPD patients, the incidence of sarcopenia (led by severe sarcopenia) and dynapenia was high compared to that among the control group of the same age. CONCLUSION: In the early stages of chronic progressive diseases like IPD, identification of sarcopenia and dynapenia is important considering the limitations of disease-preventive effects in treatments applied after diagnosis.
AIM: In this study, the aim was to identify the incidence of sarcopenia and dynapenia according to disease stage among idiopathic Parkinson's disease (IPD) patients and collect data to illuminate precautions related to reducing the disease load. METHOD: The study was completed with 166 patients divided by stage according to modified Hoehn and Yahr (HYR) criteria and 249 healthy volunteers aged from 18 to 39 and 68 to 75 years met the inclusion criteria. In our prospective and cross-sectional study, patients with IPD according to "UK Brain Bank" diagnostic criteria had the Unified Parkinson's Disease Rating Scale (UPDRS) and HYR scales applied. The patient and control groups had skeletal muscle mass index (SMMI), muscle power, and physical performance assessed. Diagnosis of sarcopenia used the European Working Group on Sarcopenia in Older People (EWGSOP) diagnostic criteria. RESULTS: In our study, in parallel with the increase in disease stage among IPD patients, the incidence of sarcopenia (led by severe sarcopenia) and dynapenia was high compared to that among the control group of the same age. CONCLUSION: In the early stages of chronic progressive diseases like IPD, identification of sarcopenia and dynapenia is important considering the limitations of disease-preventive effects in treatments applied after diagnosis.
Authors: Alfonso J Cruz-Jentoft; Francesco Landi; Eva Topinková; Jean-Pierre Michel Journal: Curr Opin Clin Nutr Metab Care Date: 2010-01 Impact factor: 4.294
Authors: Gulistan Bahat; Asli Tufan; Fatih Tufan; Cihan Kilic; Timur Selçuk Akpinar; Murat Kose; Nilgun Erten; Mehmet Akif Karan; Alfonso J Cruz-Jentoft Journal: Clin Nutr Date: 2016-02-11 Impact factor: 7.324
Authors: Marjolein A van der Marck; Heleen C Dicke; Ergun Y Uc; Zippora H A Kentin; George F Borm; Bastiaan R Bloem; Sebastiaan Overeem; Marten Munneke Journal: Parkinsonism Relat Disord Date: 2011-11-18 Impact factor: 4.891
Authors: Davide L Vetrano; Maria S Pisciotta; Alice Laudisio; Maria R Lo Monaco; Graziano Onder; Vincenzo Brandi; Domenico Fusco; Beatrice Di Capua; Diego Ricciardi; Roberto Bernabei; Giuseppe Zuccalà Journal: J Am Med Dir Assoc Date: 2018-02-12 Impact factor: 4.669
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Luís César de Medeiros; Marcella Campos Lima da Luz; Jarson Pedro da Costa Pereira; Gleyce Kelly Araújo Bezerra; Poliana Coelho Cabral Journal: Neurol Sci Date: 2021-10-22 Impact factor: 3.307
Authors: Robert C Stassen; Kostan W Reisinger; Moaath Al-Ali; Martijn Poeze; Jan A Ten Bosch; Taco J Blokhuis Journal: J Clin Med Date: 2020-06-29 Impact factor: 4.241
Authors: Danielle Pessoa Lima; Samuel Brito de Almeida; Janine de Carvalho Bonfadini; João Rafael Gomes de Luna; Madeleine Sales de Alencar; Edilberto Barreira Pinheiro-Neto; Antonio Brazil Viana-Júnior; Samuel Ranieri Oliveira Veras; Manoel Alves Sobreira-Neto; Jarbas de Sá Roriz-Filho; Pedro Braga-Neto Journal: PLoS One Date: 2020-03-19 Impact factor: 3.240
Authors: Danielle Pessoa Lima; Samuel Brito de Almeida; Janine de Carvalho Bonfadini; Emmanuelle Silva Tavares Sobreira; Patrícia Gomes Damasceno; Antonio Brazil Viana Júnior; Madeleine Sales de Alencar; João Rafael Gomes de Luna; Pedro Gustavo Barros Rodrigues; Isabelle de Sousa Pereira; André Luis de Castro Gadelha; Liliane Maria de Oliveira; Érica Carneiro Barbosa Chaves; Vlademir Gomes Carneiro; Rayane Rodrigues Monteiro; Thatyara Almeida de Macedo Costa; Lucas Helal; Joseph Signorile; Lidiane Andréa Oliveira Lima; Manoel Alves Sobreira-Neto; Pedro Braga-Neto Journal: BMJ Open Date: 2020-10-12 Impact factor: 2.692